Somerset Indus Capital Partners has smashed past its fundraising target, closing its third fund at nearly USD 288 million -- well above the planned USD 250 million— betting big on a future where financial returns and social impact go hand in hand.

 

The development not only cements its position as a leading healthcare-focused private equity player in India but also signals surging investor confidence in its healthcare-focused, impact-driven strategy.

 

The oversubscribed Fund III drew heavyweight backing from a broad mix of global institutional investors, including Development Finance Institutions, investment firms, insurers, and family offices spanning Europe, the United States, and Southeast Asia. A strong re-up rate from existing backers, combined with fresh commitments from marquee investors, underscores growing faith in the firm’s “Capital for Change” approach.

 

The new fund will double down on one of India’s most urgent challenges: expanding healthcare access for the country’s “missing middle,” particularly across Tier II and Tier III cities. Somerset plans to channel capital into scalable businesses delivering affordable, high-quality care across healthcare delivery, pharmaceuticals, medical devices, diagnostics, and allied sectors.

 

“The successful fund raise is a strong endorsement of our strategy and execution capabilities. We are grateful for the continued trust of our Limited Partners who share our conviction that impact and financial performance can be mutually reinforcing,” said Avinash Kenkare, Partner, Somerset Indus Capital Partners.

 

“India’s healthcare ecosystem is undergoing a structural transformation, particularly beyond the metros. Fund III positions us to deepen our presence in underserved markets and partner with entrepreneurs building scalable healthcare platforms. We remain committed to delivering measurable impact alongside sustainable financial returns,” added Mayur Sirdesai, Partner, Somerset Indus Capital Partners.

 

Typically deploying USD 15–40 million per investment, Somerset retains the firepower to scale up to USD 60–80 million deals through co-investments with its LP network—allowing it to chase larger, high-quality opportunities without compromising capital discipline. 

 

The firm is targeting transformative bets across preventive care, OPD-linked insurance, healthcare financing, embedded insurance, generics, MedTech innovation, and diagnostics platforms aimed at expanding access beyond metro markets.

 

Fund III is already in motion, with three investments under its belt: Cyrix Healthcare, Printmann Offset, and NU Hospitals—all showing early positive performance.

 

The firm’s track record adds further weight. Fund I has delivered roughly 4.0x DPI, while Fund II is heading toward exits, with its first realization in September 2025 clocking in at around 4x MOIC.